MiMedx Group, Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $418.6M | $348.9M | $321.5M | $267.8M | $242.0M | $248.2M | $299.3M | $359.1M |
| Cost of Revenue | $73.0M | $60.1M | $54.6M | $48.3M | $39.6M | $39.3M | $43.1M | $36.4M |
| Gross Profit | $345.6M | $288.8M | $266.8M | $219.5M | $202.4M | $208.9M | $256.2M | $322.7M |
| Gross Margin | 82.6% | 82.8% | 83.0% | 82.0% | 83.6% | 84.2% | 85.6% | 89.9% |
| Operating Expenses | ||||||||
| Research & Development | $15.1M | $12.3M | $12.7M | $12.7M | $9.9M | $11.7M | $11.1M | $15.8M |
| SG&A Expense | $266.2M | $225.1M | $211.1M | $208.7M | $194.8M | $181.0M | $198.2M | $258.5M |
| Operating Income | $63.9M | $58.9M | $37.1M | $-14.7M | $-7.1M | $-45.4M | $-21.2M | $-3.9M |
| Operating Margin | 15.3% | 16.9% | 11.5% | -5.5% | -2.9% | -18.3% | -7.1% | -1.1% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | $66.3M | $57.3M | $30.6M | $-19.7M | $-12.1M | $-61.5M | $-25.6M | $-3.4M |
| Income Tax Expense | $17.7M | $15.3M | $-36.8M | $206.0K | $247.0K | $-12.3M | $-5.0K | $26.6M |
| Net Income | $48.6M | $42.4M | $58.2M | $-30.2M | $-10.3M | $-49.3M | $-25.6M | $-30.0M |
| Net Margin | 11.6% | 12.2% | 18.1% | -11.3% | -4.2% | -19.9% | -8.5% | -8.3% |
| EPS (Basic) | $0.33 | $0.29 | $0.40 | $-0.33 | $-0.15 | $-0.77 | $-0.24 | $-0.28 |
| EPS (Diluted) | $0.32 | $0.28 | $0.37 | $-0.33 | $-0.15 | $-0.77 | $-0.24 | $-0.28 |
| Shares Outstanding (Basic) | 147.8M | 147.0M | 116.5M | 112.9M | 110.4M | 108.3M | 106.9M | 105.6M |
| Shares Outstanding (Diluted) | 149.7M | 149.0M | 146.0M | 112.9M | 110.4M | 108.3M | 106.9M | 105.6M |
| Dividends Per Share | — | — | — | — | — | — | — | — |